Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | SNCA | P37840 | 6/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947954 | 0.92 | KMT2A (0.61) | LTA4HPLA2G2AKMT2AHTR2ATRPV1 | |
| SCHEMBL5947635 | 0.86 | HTR2A (0.52) | LTA4HPLA2G2AKMT2AHTR2ATRPV1 | |
| SCHEMBL5947367 | 0.84 | KMT2A (0.65) | LTA4HPLA2G2AKMT2AHTR2ATRPM8 | |
| SCHEMBL2534484 | 0.84 | HTR2A (0.71) | LTA4HPLA2G2AKMT2AHTR2ATRPM8 | |
| SCHEMBL5947226 | 0.83 | HTR2A (0.64) | LTA4HPLA2G2AKMT2AHTR2ATRPV1 | |
| SCHEMBL5947613 | 0.83 | HTR2A (0.66) | LTA4HPLA2G2AKMT2AHTR2ATRPM8 | |
| SCHEMBL5947562 | 0.83 | HTR2A (0.68) | LTA4HPLA2G2AKMT2AHTR2ATRPM8 | |
| SCHEMBL5947104 | 0.82 | HTR2A (0.67) | LTA4HPLA2G2AKMT2AHTR2ATRPM8 | |
| SCHEMBL5947129 | 0.82 | KMT2A (0.62) | LTA4HPLA2G2AKMT2AHTR2ATRPV1 | |
| SCHEMBL5948177 | 0.81 | SNCA (0.57) | LTA4HPLA2G2AKMT2AHTR2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | claimed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | claimed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | LTA4H 820/4885PLA2G2A 1697/4885KMT2A 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.